SciSparc Ltd. is a biotechnology company focused on the development and commercialization of innovative treatments for various medical conditions, particularly those related to the central nervous system. The company is engaged in advancing therapies that aim to address significant unmet needs, utilizing its proprietary platform to explore and enhance the effectiveness of cannabinoid-based treatments. Through its research and development efforts, SciSparc aims to create novel solutions that enhance patient outcomes and improve quality of life in underserved therapeutic areas. Read More
TEL AVIV, Israel, June 04, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced the closing of its acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum").
Toronto, Ontario – June 3, 2026 – TheNewswire – NeuroThera Labs Inc. (TSXV: NTLX) (the “Company” or “NeuroThera”), a clinical-stage biotech company and a majority-owned subsidiary of SciSparc Ltd. (Nasdaq: SPRC), is pleased to announce that it has closed its previously announced acquisition (the “Transaction”) of an aggregate of 56,375 ordinary shares (the “Purchased Shares”) in the capital of CliniQuantum Ltd. (“CliniQuantum”), representing approximately 54.01% of the issued and outstanding ordinary shares of CliniQuantum, pursuant to a share purchase agreement dated March 9, 2026, as amended by an amending agreement dated April 30, 2026 (collectively, the “SPA”), among the Company, CliniQuantum and the holders of the Purchased Shares (collectively, the “Selling Shareholders”). The Transaction was initially announced by news release dated March 10, 2026 and updated by news release dated May 27, 2026.
TEL AVIV, Israel, May 28, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, received a conditional regulatory approval from the TSX Venture Exchange (“TSX”) for the acquisition of approximately 54% interest in CliniQuantum Ltd. ("CliniQuantum") (the Transaction”).
TEL AVIV, Israel, March 16, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has reported that pursuant to NeuroThera’s ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”), a patent application has been filed by Clearmind with the Intellectual Property Department in Hong Kong, China, for a innovative combination therapy designed to treat major depressive disorder (MDD).
Innovative non-hallucinogenic approach combines MEAI with Palmitoylethanolamide to tackle major depressive disorder, addressing a surging market expected to surpass $25 billion by 2030
TEL AVIV, Israel, March 12, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system (CNS) disorders, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine Inc. with the publication of an international patent application under the Patent Cooperation Treaty (PCT) for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as fatty liver disease).
TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, in which SciSparc holds a controlling interest of approximately 75%, has entered into a definitive share purchase agreement (the "SPA"), between NeuroThera, CliniQuantum Ltd. (“CliniQ”) and the Selling Shareholders (as defined below) to acquire approximately 54.01% of the issued and outstanding ordinary shares of CliniQ (the "CliniQ Shares") on a fully diluted basis immediately prior to the closing of the transaction (the “Transaction”). CliniQ is a quantum technology company holding patents from Ramot at the Tel Aviv University, in the field of quantum simulation and quantum Monte Claro.
Innovative non-hallucinogenic treatment combines MEAI with Palmitoylethanolamide to address obesity and metabolic dysfunction-associated steatotic liver disease, tapping into a rapidly growing market projected to exceed $200 billion by 2035
Following the reverse share split, the Company will have approximately 565,000 outstanding shares, out of which approximately 561,533 will be publicly held
